From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
May 27, 2021
Philadelphia, PA, May 27, 2021 – IntegriChain, delivering Life Sciences’ only comprehensive data and business process platform for market access, today announced that two senior Advisory experts will present at Informa’s upcoming Medicaid & GP Congress. Jeff Baab, Vice President, Rupal Patel, Senior Director, and Manish Rathod, Executive Director of Industry Solutions, are all experts in the latest regulatory landscape affecting Contracts & Pricing teams, advising Life Sciences manufacturers of all sizes and complexity on the impacts of current and pending regulations. IntegriChain is a sponsor of the virtual conference, which runs June 8-11, 2021.
“For Life Sciences manufacturers, the regulatory landscape is muddled with numerous new rules and pending regulations that affect both their government and commercial channels as well as short- and long-term planning,” said Baab. “At IntegriChain, it’s our job to interpret current and pending regulatory changes — and their impact on Contracts & Pricing teams, processes, and compliance requirements — for hundreds of manufacturers. We look forward to these sessions to provide clarity and focus for attendees.”
IntegriChain’s sessions during Medicaid & GP Congress are as follows.
Industry-Only Solution Summit June 19, 9:30 am ET Rathod will lead this small group, interactive breakout session, for a demonstration of IntegriChain’s best-in-class process for Government Pricing and Reporting.
Current Final Rule Updates and Review June 21, 1:15 pm ET Late last year, the Centers for Medicare & Medicaid Services (CMS) finalized regulatory changes to modernize Medicaid prescription drug purchasing and propel payment innovation by providing states, private payers, and manufacturers more flexibility to enter into value-based purchasing arrangements for prescription drugs. Patel will be joined in this session by Kristie Gurley, an Associate at Covington & Burling LLP, and together they will review key aspects of the Final Rule, potential changes to the Final Rule, and the impact on manufacturers, including:
Legal and Compliance Closing Fireside Chat June 21, 2:00 pm ET Baab will moderate an interactive discussion featuring a panel of experienced attorneys providing insight into the most pressing issues. Panelists include Meena Datta, a Partner at Sidley Austin, LLP; Stephanie Trunk, a Partner at Arent Fox; Jennifer Plitsch, a Partner at Covington & Burling: Alice Valder Curran, a Partner at Hogan Lovells; and Christopher Schott, a Partner at Latham & Watkins LLP.
About IntegriChain’s Government Pricing & Compliance Advisory Services Experienced IntegriChain consultants advise Life Sciences manufacturers on strategic and compliance matters in the midst of an the ever-changing government and program regulations including:
About IntegriChain IntegriChain is Life Sciences’ data and application backbone for patient access and therapy commercialization. More than 250 manufacturers rely on IntegriChain’s ICyte Platform to orchestrate commercial and government payer contracting, patient services, and distribution channels. ICyte is the first and only platform that unites the financial, operational, and commercial data sets required to support therapy access in the era of specialty and precision medicine. With ICyte, Life Sciences innovators are digitalizing labor-intensive processes – freeing up their best talent to identify and resolve coverage and availability hurdles and to manage pricing and forecasting complexity. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm. The company is headquartered in Philadelphia, PA, with offices in Ambler, PA; Raleigh, NC, and Pune, India. For more information, visit www.integrichain.com, or follow us on Twitter @IntegriChain and LinkedIn.
Contact Jennifer Guinan, Sage Strategic Marketing, 610.410.8111, Jennifer@sagestrat.com
Save the date!
Webinars & Resources
See List
